ClinicalTrials.gg
CompletedNCT05616156Updated Oct 22, 2026

The Cre8™ BTK Post Market Clinical Follow-up Study

An observational study in Peripheral Arterial Disease, sponsored by CID S.p.A.. Completed at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by CID S.p.A. · Observational

How we know

Updated Oct 22, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Peripheral Arterial Disease with a site in Italy — 16 open to participants now, 21 under way, 2 of them phase 3. Peripheral Arterial Disease · Italy.

Enrollment
34th of 36
30 · median 204
Started
2023
with 9 others
Observational
36 of 78
10 open now
Registered
57th of 78
by date
Lead sponsor
3 of 78
CID S.p.A.

Among the 78 studies in Peripheral Arterial Disease with a site in Italy, this one is the 34th largest by enrollment of the 36 observational ones that give a count, is one of 10 that started in 2023, is one of 36 observational ones, and was the 57th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

16 of the 78 studies in Peripheral Arterial Disease with a site in Italy are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Peripheral Arterial Disease with a site in Italy, or all of them as a file.
02

Study summary

Cre8™ BTK is a CE marked drug eluting stent, integrally coated with i-Carbofilm, loaded with formulated Sirolimus for the treatment of infrapopliteal peripheral artery disease.

The aim of this post-market retrospective study protocol P32102 is to collect clinical data of patient treated with Cre8™ BTK stent in routine clinical practice.

In order to obtain long-term follow-up data, the data collection will be limited to patients that have been treated with the Cre8™ BTK stent at least 12 months prior to the study start.

Read the detailed description

The objective of this post-market observational study is to collect retrospective clinical data on the implantable medical device Cre8™ BTK in an unselected population, in the current clinical practice treated within the intended use. Data will be collected via medical chart review in anonymous form to assess the safety and efficacy of the device.

The Cre8™ BTK stent is made of cobalt-chromium alloy (L605) and it is coated with iCarbofilm™, a thin carbon film with a high density turbostratic structure substantially identical with that of the pyrolytic carbon used for mechanical cardiac valve discs. Coating the substrate with iCarbofilm™ provides it with the bio- and haemocompatible characteristics of pyrolytic carbon, without affecting the physical and structural properties of the substrate itself. The outer surface of the stent has dedicated grooves, fully coated with iCarbofilm™, for containing the pharmaceutical formulation Amphilimus™, which is composed of the drug sirolimus and a mixture of long-chain fatty acid.

The specific drug dosage is 0.9 μg/mm2 corresponding to a minimum dose of 50 μg on the smaller stent (2.25x8mm) and a maximum dose of 395 μg on the larger stents (4.0x38mm and 3.5x46mm). Two radiopaque platinum markers, positioned at each end of the stent, allow to correctly position it over the lesion to be treated.

03

Conditions studied

  • Peripheral Arterial Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with infrapopliteal ischemic obstruction, implanted with at least one Cre8™ BTK drug eluting stent at least 12 months prior to the start date of the retrospective data collection.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has been implanted with at least one Cre8™ BTK device according to the indications described in the Instructions for Use (IFU),
  • Study device implantation date is at least one year (12 months) prior to the starting date of the retrospective anonymous data collection.

Exclusion criteria

Exclusion Criteria:

  • Patients treated less than 12 months prior to study start
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
30 participants (actual)
Patient registry
No

Interventions

  • DeviceCre8™ BTK

    Implant of Cre8™ BTK stent the treatment of infrapopliteal peripheral artery disease

06

What researchers measure

Primary outcomes

  1. Rate of Major Adverse Events (MAE)

    Composite endpoint of all causes of death, unplanned target limb major amputation and/or clinically indicated target lesion revascularization (TLR)

    Time frame: 12 months

Secondary outcomes

  1. Primary patency

    Primary patency is defined as absence of clinically-driven target lesion revascularization or binary restenosis. Binary restenosis is defined as a peak systolic velocity ratio (PSVR) \>2.4 (Duplex Ultrasound evaluation)

    Time frame: 6 months and 12 months

  2. Limb-salvage rate (LSR)

    Limb-salvage rate (LSR) is defined as rate of patients free from major amputation. Major amputation is defined as at or above ankle, as opposed to minor amputation being at or below metatarsus preserving functionality of foot

    Time frame: 6 months and 12 months

  3. Secondary patency

    Patency following successful target lesion revascularization (TLR)

    Time frame: 6 months and 12 months or latest patency data available

  4. Death

    Death within 30 days of the index procedure

    Time frame: 30 days

  5. Clinically driven Target Lesion Revascularization

    Clinically driven Target Lesion Revascularization

    Time frame: 6 months and 12 months

  6. Target limb ischemia

    Target limb ischemia requiring surgical intervention or surgical repair of target vessel rate

    Time frame: 6 months and 12 months

  7. Rutherford category measurement

    Rutherford category measurement

    Time frame: pretreatment, 6 months and 12 months

  8. Evaluation of Serious Adverse Events (SAEs)

    Evaluation of Serious Adverse Events (SAEs)

    Time frame: 6 months and 12 months

  9. Acute success (device and procedural) within discharge

    Clinical device success defined as successful delivery and deployment of the stent(s) at the intended target lesion (this includes successful delivery and deployment of multiple stents) and final residual stenosis of the target lesion minor or equal to 30%, assessed by visual estimation and clinical device success without the occurrence of MAE during the hospital stay

    Time frame: 24/72 hours

07

Study locations

2 sites
  • Pliclinico Abano terme
    Abano Terme, Padova, Italy
  • Grande Ospedale Metropolitano Bianchi Melacrino Morelli
    Reggio Calabria, Italy
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2023 to primary completion in Nov 2023, 7 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Feb 2023 → Apr 2023, primary completion Jun 2023 → Nov 2023 and completion Jul 2023 → Jan 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2022
First posted
Nov 15, 2022
StartActual
Apr 12, 2023was Feb 2023
Primary completionActual
Nov 24, 2023was Jun 2023
CompletionActual
Jan 31, 2024was Jul 2023
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 22, 2026
Start date
Feb 2023→Apr 12, 2023 (actual)
Oct 22, 2026
Primary completion
Jun 2023→Nov 24, 2023 (actual)
Oct 22, 2026
Study completion
Jul 2023→Jan 31, 2024 (actual)
Oct 22, 2026
Enrollment
50 (estimated)→30 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Status unknown→Completed
    Start date Feb 2023→Apr 12, 2023 (now actual)
    Primary completion Jun 2023→Nov 24, 2023 (now actual)
    Study completion Jul 2023→Jan 31, 2024 (now actual)
    Enrollment 50 (estimated)→30 (actual)
    + 2 other changes: index terms and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05616156
Lead sponsor
CID S.p.A.
Collaborators
Meditrial Europe Ltd.
Responsible party
Sponsor
First posted
Nov 15, 2022
Start date
Apr 12, 2023
Primary completion
Nov 24, 2023
Completion
Jan 31, 2024
Last update
Oct 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion